Why Boston Scientific Stock Plummeted Today

Core Insights - Boston Scientific's shares fell 16% following its fourth-quarter earnings report despite surpassing Wall Street expectations for sales and adjusted earnings per share (EPS) growth of 16% and 14% respectively [1] - The company's guidance for Q1 and 2026 was slightly below analysts' expectations, leading to a negative market reaction [1] Financial Performance - The company achieved 18% sales growth in its core cardiovascular segment and 12% growth in its medsurg unit [4] - Revenue growth of 12% or higher was recorded across all geographical regions [4] - Boston Scientific is projected to achieve 11.25% sales growth in 2026 and has guided for $4.2 billion in free cash flow (FCF) in 2026, up from $3.7 billion this year [4] Strategic Positioning - The company has made approximately 40 acquisitions over the past decade and maintains about 45 active investments in its venture capital portfolio [2] - Boston Scientific is currently involved in over 65 ongoing trials, indicating a robust pipeline of technologies [2] - The company is viewed as an innovation leader, which is expected to support continued growth [2]